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Background: Central venous catheters are significant risk factors for bloodstream 
infection (BSI), which are directly associated with increased morbidity and mortality.
Methods: This study was a retrospective cohort study for the time period of July 2011–
June 2014 in patients with central line-associated bloodstream infection (CLABSI) to 
determine the microbiological profile and antimicrobial adequacy of patients with CLABSI 
in a tertiary hospital.
results: One hundred and twenty-one CLABSI cases were identified. Ninety-two 
percent (n = 111) of patients had monomicrobial BSI. Gram-negative bacteria were the 
most prevalent (49%, n = 63), with Klebsiella spp. predominating (30%, n = 19). Among 
the Gram-positive bacteria (n = 43, 33%), coagulase-negative staphylococci was the 
major pathogen (58%, n = 25), and all isolates were methicillin resistant. Antimicrobial 
therapy was assessed as adequate in 81% (n = 98) of cases. In-hospital mortality was 
36% (n = 43 cases).
conclusion: Our CLABSI patients had a high mortality, although antimicrobial therapy 
was appropriate. Gram-negative bacteria were responsible for almost half of the cases 
and there was a high rate of bacteria resistance to extended-spectrum antibiotics.
Keywords: central line-associated infection, inadequate antimicrobial therapy, mortality, blood stream infection, 
central venous catheters
inTrODUcTiOn
Central venous catheters (CVCs) are essential for the care of seriously ill patients (1, 2). However, 
CVCs are significant risk factors for bloodstream infection (BSI), which are directly associated with 
increased morbidity and mortality, length of hospital stay, and medical and hospital costs (2–4). 
Each year in the United States, there are an estimated 80,000 new cases of central line-associated 
bloodstream infection (CLABSI), resulting in over 28,000 deaths among patients in intensive care 
units, with an attributable cost of more than 2.3 billion dollars (5).
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To improve antimicrobial therapy for BSI, it is neces-
sary to understand the microorganism profile as well as the 
antimicrobial susceptibility of these microorganisms (6–8). 
In  a recent publication from our hospital, which analyzed the 
impact of the implementation of a sepsis protocol, 60% of our 
patients developed severe sepsis and septic shock outside of 
the Emergency Department, which increases the probability of 
nosocomial infection with antibiotic-resistant microorganisms 
(9, 10). There are serious concerns about the rapid increase 
of multidrug resistant bacteria, mainly the Gram-negative 
microorganisms (10).
Thus, the objectives of this study were to determine the 
microbiological profile and antimicrobial adequacy of patients 
with CLABSI in a tertiary hospital.
MaTerials anD MeThODs
This study was conducted in a 629-bed tertiary care (Hospital 
Israelita Albert Einstein), private hospital in São Paulo, Brazil, 
with approximately 194,000 patient-days yearly. This study 
was approved by the Institutional Review Board (CAAE # 
40993115.8.0000.0071) with a waiver of informed consent.
We performed a retrospective cohort study for the time period 
of July 2011–June 2014, in patients with central line-associated 
bloodstream infection.
Definitions
Central lines were defined using the definition of the National 
Healthcare Safety Network (NHSN) (11). The NHSN methodol-
ogy for CLABSI employs active surveillance with standardized 
definitions by infection preventionists. The definition of CLABSI 
was an NHSN defined laboratory-confirmed bloodstream 
infection that was not secondary to an infection at another body 
site (11).
The esKaPe group
ESKAPE group pathogens were defined as the following: van-
comycin resistant Enterococcus faecium, methicillin-resistant 
Staphylococcus aureus, extended-spectrum beta-lactamase—
producing Escherichia coli and Klebsiella species, Klebsiella 
pneumoniae carbapenemase-hydrolyzing beta-lactamases, 
multidrug resistant Acinetobacter species, resistant Pseudomonas 
aeruginosa, and Enterobacter species (12).
antimicrobial Therapy
As in our previous study (10), antimicrobial therapy was consid-
ered appropriate if the bacterial species identified in blood culture 
was susceptible to at least one of the antibiotics administered 
within 24 h after the collection of culture. If the isolated microor-
ganism was not susceptible by in vitro testing to the antibiotic(s) 
used, the therapy was considered inadequate. The microbiology 
laboratory has an alert system to notify physicians of patients 
with positive blood culture and their Gram stain results. Also 
the proper antimicrobial dose, proper interval administration, 
monitoring of drug levels when appropriate, and avoidance of 
unwanted drug interactions were evaluated (6) by the pharma-
ceutical hospital in our medical routine.
Microbiological Methods
All samples were identified by manual or automated methods 
and confirmed using the Vitek 2 system (bioMerieux Vitek, 
Inc., Hazelwook, MO, USA). The same organism with identical 
antimicrobial susceptibility profiles from the same or different 
anatomic sites in the same patient was considered a single isolate. 
Antimicrobial susceptibility testing was performed by an auto-
mated method or by disk diffusion as described by the Clinical 
and Laboratory Standards Institute (13).
statistical analysis
Continuous variables were described by mean and SD or median 
and interquartile range (IQR). Categorical variables were 
described as absolute numbers and percentages. Logistic regres-
sion models were used to investigate variables associated with 
death or adequate antimicrobial therapy. Variables with P < 0.1 in 
the univariate analysis were included in the multivariate models, 
which were submitted to stepwise method to select the best subset 
of predictors to each outcome. Results were presented as odds 
ratios and 95% confidence intervals. The level of significance was 
set at 0.05 and analyses were performed with statistical package 
R (14).
resUlTs
A total of 121 CLABSI cases were identified from July 2011 to 
June 2014. The mean age of the cases was 67 years (SD = 18), 
and the median length of hospital stay was 43 days (exact median 
cannot be calculated as two patients remain hospitalized). Of 
the cases, 56% (n = 68) were male. ESKAPE group pathogens 
accounted for 21% (n = 25) of the cases. Polymicrobial CLABSIs 
accounted for 9% (n = 11) of the cases. Antimicrobial therapy 
was assessed as adequate in 81% (n = 98) of cases. Cardiac dys-
function occurred in 63% (n = 76) and respiratory dysfunction 
occurred in 52% (n = 63). In-hospital mortality was 36% (n = 43 
cases) (Table 1).
In univariate analysis, variables potentially associated with 
death (P <  0.1) among patients with CLABSI (Table  2) were 
age, liver dysfunction, cardiac dysfunction, renal dysfunction, 
hematologic dysfunction, respiratory dysfunction, heart failure, 
polymicrobial infection, and adequate antimicrobial infection. In 
the final multivariate model, after stepwise selection, the follow-
ing variables were statistically significant: age (OR: 1.1, p < 0.01), 
liver dysfunction (OR: 4.3, p = 0.01); hematologic dysfunction 
(OR: 6.1, p = 0.01); and renal dysfunction (OR: 10.8, p < 0.01); 
renal failure (OR: 0.2, p = 0.03); cancer (OR: 4.3, p = 0.04); and 
polymicrobial infection (OR: 5.9, p = 0.04).
Appropriate antimicrobial treatment was administered in 81% 
of patients (n = 98). All lines in patients with confirmed CLABSI 
were removed. No variable predicted antimicrobial inadequacy 
(Table 3). Although there was a trend toward increased mortal-
ity with inadequate antimicrobial therapy, it was not statistically 
significantly different.
TaBle 1 | Demographic and clinical characteristic of patients with 
central line-associated bloodstream infection.
Variables (n = 121)
n %
Age—mean (SD) 67 18
Length of stay—median (IQR) 43 22–81a
Male 68 56.2
ESKAPE group pathogen 25 20.7
Polymicrobial infection 11 9.1
Appropriate antibiotic therapy 98 81.0
Respiratory dysfunction 63 52.1
Cardiac dysfunction 76 62.8
Renal dysfunction 38 31.4
Liver dysfunction 36 29.8
Hematologic dysfunction 37 30.6
Crude mortality rate 43 35.5
ESKAPE, Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Enterobacter spp.; IQR, interquartile range.
aMinimum and maximum length of stay—2 and 600 days.
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Among patients identified with CLABSI, 92% (n =  111) of 
patients had monomicrobial BSI. Gram-negative bacteria were 
the most prevalent (49%, n = 63), with Klebsiella spp. predomi-
nating (30%, n = 19), followed by P. aeruginosa (17.5%, n = 11), 
E. coli (15.9%, n =  10), and Enterobacter spp. (12.7%, n =  8). 
Among the Gram-positive bacteria (n =  43, 33%), coagulase-
negative staphylococci was the major pathogen (58%, n =  25), 
and all isolates were methicillin resistant, followed by S. aureus 
(23.3%, n = 10) and Enterococcus spp. (14.0%, n = 6). The great 
majority of S. aureus and Enterococcus spp. were methicillin 
resistant (90%, n = 9) and vancomycin resistant (83.3%, n = 5), 
respectively. Among the fungi (18%, n = 23), Candida parapsilosis 
and Candida albicans were the most prevalent (30%, n = 7, and 
22%, n = 5, respectively).
DiscUssiOn
Our findings identified the pathogen profile in patients with 
CLABSI. Regardless of the hospital unit where CLABSI 
occurred, Gram-negative bacteria, were the most common 
pathogens, especially Klebsiella spp. (30% of all Gram-negative 
pathogens), and nearly all of which (95%) were resistant to the 
third- and fourth-generation cephalosporins. This differs from 
international studies, including a meta-analysis that assessed 18 
studies carried out in different intensive care units, which showed 
that Gram-positive bacteria are the most prevalent pathogens 
(15). In the Brazilian Surveillance and Control of Pathogens of 
Epidemiological Importance Project, the spectrum of pathogens 
was similar to the present study (16). Fisman et al. demonstrated 
that geography has a direct influence on the development of BSI 
caused by Gram-negative bacteria (17).
In our earlier investigation, evaluating patients with severe 
sepsis and septic shock, the bacterial profile was similar, with a 
predominance of Gram-negative organisms; however, there was 
a greater prevalence of E. coli (10). There was a great difference in 
the proportion of BSI caused by fungi, only 1.5% of cases in the 
previous study (10), compared to 18% in the current study with 
65% in-hospital mortality.
The most common microorganisms responsible for CLABSI 
change over time. For example, the best practices in ICU care 
have reduced the proportion of CLABSI due to Gram-positive 
bacteria (15, 18, 19).
TaBle 2 | risk factors associated with death in patients with central line-associated bloodstream infection.






Univariate analysis Multivariate analysis
Or ci 95%  
(ll–Ul)
P Or ci 95%  
(ll–Ul)
P
Age (years), mean (SD) 64.7 (19.4) 71.2 (14.4) 1.0 (1.0–1.04) 0.06 1.1 (1.0–1.1) <0.01
Male 41 (52.6) 27 (62.8) 1.5 (0.7–3.3) 0.28
Organs dysfunction
 Liver dysfunction 16 (20.5) 20 (46.5) 3.4 (1.5–7.6) 0.01 4.3 (1.3–16.0) 0.01
 Cardiac dysfunction 41 (52.6) 35 (81.4) 4.0 (1.6–9.6) 0.01 3.1 (0.7–15.2) 0.16
 Renal dysfunction 14 (17.9) 24 (55.8) 5.8 (2.5–13.3) <0.01 10.8 (2.5–60.0) <0.01
 Hematologic dysfunction 19 (24.4) 18 (41.9) 2.2 (1.0–5.0) 0.05 6.1 (1.6–27.1) 0.01
 Respiratory dysfunction 34 (43.6) 29 (67.4) 2.7 (1.2–5.8) 0.01
Comorbidities
 Diabetes mellitus 27 (34.6) 14 (32.6) 0.9 (0.4–2.0) 0.82 0.3 (0.1–1.0) 0.057
 Renal failure 15 (19.2) 6 (14.0) 0.7 (0.2–1.9) 0.47 0.2 (0.1–0.8) 0.03
 Hypertension 33 (42.3) 13 (30.2) 0.6 (0.3–1.3) 0.19
 Heart failure 6 (7.7) 10 (23.3) 3.7 (1.2–10.9) 0.02 18.3 (2.8–182.0) 0.01
 Cancer 27 (34.6) 19 (44.2) 1.5 (0.7–3.2) 0.30 4.3 (1.2–19.7) 0.04
 Transplantation 11 (14.1) 2 (4.7) 0.3 (0.1–1.4) 0.13
Polymicrobial infection 4 (5.1) 7 (16.3) 3.6 (1.1–13.1) 0.05 5.9 (1.1–34.8) 0.04
ESKAPEa pathogen causing 
bloodstream infection
19 (24.4) 6 (14.0) 0.5 (0.2–1.4) 0.18
Adequate antimicrobial therapy 67 (85.9) 31 (72.1) 0.4 (0.2–1.1) 0.07
aESKAPE, Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter spp.; OR, odds ratio; CI, confidence interval; LL, lower limit;  
UL, upper limit.
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The higher prevalence of Klebsiella spp. was also identified in 
a previous study (16). Also previous findings descri bed by Correa 
et  al. warned off the increased resistance of K.  pneumoniae 
(20) and reinforced by the European Antimicro bial Resistance 
Surveillance System in its latest report of hospitals (2011–2012), 
which was analyzed in 29 European countries (21).
Heart failure was shown to be an independent risk factor for 
death. In addition, the presence of liver, renal, and hematological 
dysfunctions significantly increased the risk of death. Moreover, 
concomitant toxicity of antimicrobial treatment of multidrug 
resistant microorganisms, particularly with prolonged duration 
of therapy, adds to the morbidity of the systemic inflammatory 
response induced by the pathogen (6, 18).
Antimicrobial therapy in a previous study was an independ-
ent predictor for lower mortality in patients with severe sepsis 
and septic shock (10). In our study, inadequacy of therapy 
showed a trend toward increased mortality. However, the 
characteristics of these patients show us that appropriate initial 
antimicrobial treatment of these cases portend a greater chance 
of error, when polymicrobial infection or ESKAPE pathogens 
are possible.
The limitations of this study include performance in a single 
center, which may not allow generalization to other hospitals. 
Although some information was retrospectively obtained from 
medical records, the patients were followed prospectively by the 
hospital epidemiology unit.
In conclusion, our CLABSI patients had a high mortality, 
although antimicrobial therapy was appropriate. Gram-negative 
bacteria were responsible for almost half of the cases and there 
was a high rate of bacteria resistance to extended-spectrum 
antibiotics.
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TaBle 3 | risk factors associated with inadequate antimicrobial therapy in patients with central line-associated bloodstream infection.





Or ci 95% 
(ll–Ul)
P Or ci 95% 
(ll–Ul)
P
Male 15 (65.2) 53 (54.1) 0.6 (0.2–1.6) 0.34
Age (years), mean (SD) 70.7 (17.5) 66.2 (18.1) 0.99 (0.96–1.1) 0.29
Organs dysfunctions
 Liver dysfunction 8 (34.8) 28 (28.6) 0.8 (0.3–2.0) 0.56
 Cardiac dysfunction 16 (69.6) 60 (61.2) 0.7 (0.3–1.8) 0.46
 Renal dysfunction 9 (39.1) 29 (29.6) 0.7 (0.3–1.7) 0.38
 Hematologic dysfunction 7 (30.4) 30 (30.6) 1.0 (0.4–2.7) 0.99
 Respiratory dysfunction 12 (52.2) 51 (52.0) 1.0 (0.4–2.5) 0.99
Polymicrobial infection 1 (4.3) 10 (10.2) 2.5 (0.3–20.6) 0.39
ESKAPE pathogen causing bloodstream infection 2 (8.7) 23 (23.5) 3.2 (0.7–14.8) 0.13 3.2 (0.7–14.8) 0.13
ESKAPE, Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterobacter spp.; OR, odds ratio; CI, confidence interval; LL: lower limit;  
UL: upper limit.
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